Clofibrate

Clofibrate

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	AU: B1 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	C10AB01 (WHO)
Legal status
Legal status	US: Discontinued
Pharmacokinetic data
Protein binding	Variable, 92–97% at therapeutic concentrations
Metabolism	Hydrolyzed to clofibric acid; hepatic glucuronidation
Elimination half-life	Highly variable; average 18–22 hours. Prolonged in renal failure
Excretion	Renal, 95 to 99%
Identifiers
IUPAC name ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
CAS Number	637-07-0
PubChem CID	2796
DrugBank	DB00636 Y
ChemSpider	2694 Y
UNII	HPN91K7FU3
KEGG	D00279 Y
ChEBI	CHEBI:3750 Y
ChEMBL	ChEMBL565 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H15ClO3
Molar mass	242.698 g/mol
3D model (JSmol)	Interactive image
Boiling point	148 °C (298.4 °F)
SMILES Clc1ccc(OC(C(=O)OCC)(C)C)cc1
InChI InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3 Y Key:KNHUKKLJHYUCFP-UHFFFAOYSA-N Y
(verify)

WikiDoc Resources for Clofibrate
Articles
Most recent articles on Clofibrate Most cited articles on Clofibrate Review articles on Clofibrate Articles on Clofibrate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Clofibrate Images of Clofibrate Photos of Clofibrate Podcasts & MP3s on Clofibrate Videos on Clofibrate
Evidence Based Medicine
Cochrane Collaboration on Clofibrate Bandolier on Clofibrate TRIP on Clofibrate
Clinical Trials
Ongoing Trials on Clofibrate at Clinical Trials.gov Trial results on Clofibrate Clinical Trials on Clofibrate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Clofibrate NICE Guidance on Clofibrate NHS PRODIGY Guidance FDA on Clofibrate CDC on Clofibrate
Books
Books on Clofibrate
News
Clofibrate in the news Be alerted to news on Clofibrate News trends on Clofibrate
Commentary
Blogs on Clofibrate
Definitions
Definitions of Clofibrate
Patient Resources / Community
Patient resources on Clofibrate Discussion groups on Clofibrate Patient Handouts on Clofibrate Directions to Hospitals Treating Clofibrate Risk calculators and risk factors for Clofibrate
Healthcare Provider Resources
Symptoms of Clofibrate Causes & Risk Factors for Clofibrate Diagnostic studies for Clofibrate Treatment of Clofibrate
Continuing Medical Education (CME)
CME Programs on Clofibrate
International
Clofibrate en Espanol Clofibrate en Francais
Business
Clofibrate in the Marketplace Patents on Clofibrate
Experimental / Informatics
List of terms related to Clofibrate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Clofibrate (tradename Atromid-S) is an organic compound. It is marketed as a fibrate. It is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well.

Complications and controversies

It can induce SIADH, syndrome of inappropriate secretion of antidiuretic hormone ADH (vasopressin).

The World Health Organization Cooperative Trial on Primary Prevention of Ischaemic Heart Disease using clofibrate to lower serum cholesterol observed excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".

Clofibrate was discontinued in 2002 due to adverse affects.

Synthesis

Clofibrate synthesis.